Gapping up
In reaction to strong earnings/guidance/SSS: SQNM +6%, IRMD +5.8%, HCA +5.2%, KONA +4.9%, (prelim Q4 restaurant sales above consensus) ACOR +4.6%, (reports prelim Q4/2015 AMPYRA sales and 2016 guidance), SCVL +4.5%, EBS +3.3%, NVRO +3.1%, FOLD +2.5%, (Provides Full-Year 2016 Strategic Outlook and Financial Guidance) EVHC +0.8%, ARAY +0.7%
M&A news: AFFX +48.6% (to be acquired by Thermo Fisher (TMO) for $14.00/share in cash; expected to be immediately accretive to TMO's adjusted EPS), (exploring strategic alternatives; also released earnings), APOL +8.2% (exploring strategic alternatives; also released earnings), (to be acquired by Shire (SHPG) for ~$45.57/share), BXLT +6% (to be acquired by Shire (SHPG) for ~$45.57/share), (acquires AbVitro fro ~$78 mln), JUNO +4.6% (acquires AbVitro fro ~$78 mln), (receives IRS ruling for the planned spin-off of its biosciences business), EBS +3.3% (receives IRS ruling for the planned spin-off of its biosciences business), (to acquire BXLT for 45.57 per share), SHPG +2.9% (to acquire BXLT for 45.57 per share), (Starboard sends letter to the Board encouraging them to pursue more real estate deals, according to the WSJ), M +1.6% (Starboard sends letter to the Board encouraging them to pursue more real estate deals, according to the WSJ)
Select metals/mining stocks trading higher: MT +8.4%, HMY +6.2%, GFI +3.9%, KGC +3.7%, AU +2.4%, RIO +1.7%, VALE +1.5%, GOLD +1%
Other news: ATV +36.4% (announces share repurchase program of $2 mln), SCON +35.2% (reported its Conductus wire achieved a significant milestone for use in High Field Magnet applications), AVXL +21.1% (announces positive dose-response data for ANAVEX 2-73 in Alzheimer's disease patients), THLD +13.9% (Threshold Pharma and Merck KGaA (MKGAY) agree upon terms for the licensing back of all rights to evofosfamide to Threshold), SGYP +12.3% (announces positive phase 1b data with its second uroguanylin analog), VPCO +11.6% (withdrew previously announced offer to issue common stock and warrants in exchange for outstanding Units sold in the July 2015 offering), MNKD +6.1% (confirms Sanofi's (SNY) termination of the License and Collaboration Agreement), OCUL +5.6% (appoints Jonathan H. Talamo, M.D., as Chief Medical Officer), ZGNX +5.6% (Initiation of Phase 3 Program for ZX008 in Dravet Syndrome), ACRX +5.5% (provides anticipated 2016 milestones; reports initiation and completion of final Phase 3 trial in the U.S. for Zalviso, NDA Resubmission), ONTY +5.5% (announces the retirement of President and CEO Robert L. Kirkman, M.D. effective January 11), SGMO +4.6% (details its milestones and objectives for 2016), WLH +4.2% (commences $50 mln of 7.00% Senior Notes due 2022), RXDX +3.8% (details its strategic priorities for 2016), ILMN +3.5% (forms new company GRAIL for early detection blood-based screening; considered significant development in the war on cancer), SCMP +3.2% (granted a sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America from Cancer Prevention Pharma), IMGN +2.8% (provides anticipated milestones for 2016), CTIC +2.5% (reports positive progress of lead clinical programs; provides outlook for 2016), ARIA +2.4% (elects Alex Denner as Chairman), AA +2% (announces $1.5 bln long-term contract with GE Aviation (GE) for jet engine components; note AA reports earnings tonight), HMSY +1.4% (discloses it & the New York State Office of the Medicaid Inspector General entered into an amendment extending the term of existing third party liability contract), XONE +1.4% (enters into an At Market Issuance Sales Agreement with FBR and MLV & Co. to sell up to $50 mln in shares of its common stock), GPRO +1.4% (slight strength following Friday's weakness), NVS +1.3% (signs licensing agreement with Surface Oncology), MEG +1.3% (Nexstar Broadcasting (NXST) reiterates its commitment to acquire Media General, and to take all necessary actions to consummate a transaction )
Analyst comments: GM +1.9% (upgraded to Outperform from Neutral at Credit Suisse), AAPL +1.4% (upgraded to Buy from Neutral at Mizuho), WFC +1.1% (upgraded to Buy from Neutral at Goldman
)
In reaction to strong earnings/guidance/SSS: SQNM +6%, IRMD +5.8%, HCA +5.2%, KONA +4.9%, (prelim Q4 restaurant sales above consensus) ACOR +4.6%, (reports prelim Q4/2015 AMPYRA sales and 2016 guidance), SCVL +4.5%, EBS +3.3%, NVRO +3.1%, FOLD +2.5%, (Provides Full-Year 2016 Strategic Outlook and Financial Guidance) EVHC +0.8%, ARAY +0.7%
M&A news: AFFX +48.6% (to be acquired by Thermo Fisher (TMO) for $14.00/share in cash; expected to be immediately accretive to TMO's adjusted EPS), (exploring strategic alternatives; also released earnings), APOL +8.2% (exploring strategic alternatives; also released earnings), (to be acquired by Shire (SHPG) for ~$45.57/share), BXLT +6% (to be acquired by Shire (SHPG) for ~$45.57/share), (acquires AbVitro fro ~$78 mln), JUNO +4.6% (acquires AbVitro fro ~$78 mln), (receives IRS ruling for the planned spin-off of its biosciences business), EBS +3.3% (receives IRS ruling for the planned spin-off of its biosciences business), (to acquire BXLT for 45.57 per share), SHPG +2.9% (to acquire BXLT for 45.57 per share), (Starboard sends letter to the Board encouraging them to pursue more real estate deals, according to the WSJ), M +1.6% (Starboard sends letter to the Board encouraging them to pursue more real estate deals, according to the WSJ)
Select metals/mining stocks trading higher: MT +8.4%, HMY +6.2%, GFI +3.9%, KGC +3.7%, AU +2.4%, RIO +1.7%, VALE +1.5%, GOLD +1%
Other news: ATV +36.4% (announces share repurchase program of $2 mln), SCON +35.2% (reported its Conductus wire achieved a significant milestone for use in High Field Magnet applications), AVXL +21.1% (announces positive dose-response data for ANAVEX 2-73 in Alzheimer's disease patients), THLD +13.9% (Threshold Pharma and Merck KGaA (MKGAY) agree upon terms for the licensing back of all rights to evofosfamide to Threshold), SGYP +12.3% (announces positive phase 1b data with its second uroguanylin analog), VPCO +11.6% (withdrew previously announced offer to issue common stock and warrants in exchange for outstanding Units sold in the July 2015 offering), MNKD +6.1% (confirms Sanofi's (SNY) termination of the License and Collaboration Agreement), OCUL +5.6% (appoints Jonathan H. Talamo, M.D., as Chief Medical Officer), ZGNX +5.6% (Initiation of Phase 3 Program for ZX008 in Dravet Syndrome), ACRX +5.5% (provides anticipated 2016 milestones; reports initiation and completion of final Phase 3 trial in the U.S. for Zalviso, NDA Resubmission), ONTY +5.5% (announces the retirement of President and CEO Robert L. Kirkman, M.D. effective January 11), SGMO +4.6% (details its milestones and objectives for 2016), WLH +4.2% (commences $50 mln of 7.00% Senior Notes due 2022), RXDX +3.8% (details its strategic priorities for 2016), ILMN +3.5% (forms new company GRAIL for early detection blood-based screening; considered significant development in the war on cancer), SCMP +3.2% (granted a sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America from Cancer Prevention Pharma), IMGN +2.8% (provides anticipated milestones for 2016), CTIC +2.5% (reports positive progress of lead clinical programs; provides outlook for 2016), ARIA +2.4% (elects Alex Denner as Chairman), AA +2% (announces $1.5 bln long-term contract with GE Aviation (GE) for jet engine components; note AA reports earnings tonight), HMSY +1.4% (discloses it & the New York State Office of the Medicaid Inspector General entered into an amendment extending the term of existing third party liability contract), XONE +1.4% (enters into an At Market Issuance Sales Agreement with FBR and MLV & Co. to sell up to $50 mln in shares of its common stock), GPRO +1.4% (slight strength following Friday's weakness), NVS +1.3% (signs licensing agreement with Surface Oncology), MEG +1.3% (Nexstar Broadcasting (NXST) reiterates its commitment to acquire Media General, and to take all necessary actions to consummate a transaction )
Analyst comments: GM +1.9% (upgraded to Outperform from Neutral at Credit Suisse), AAPL +1.4% (upgraded to Buy from Neutral at Mizuho), WFC +1.1% (upgraded to Buy from Neutral at Goldman
)